Is BBOT or BCAX more undervalued in 2026?

CirclFi compares BridgeBio Oncology Therapeutics (BBOT) and Bicara Therapeutics Inc. (BCAX) using 13 institutional-grade valuation models. BBOT has a Quality of Company score of 6.2/10 while BCAX scores 4.3/10.

Which is a better buy — BBOT or BCAX?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do BBOT and BCAX valuations compare?

BBOT at $8.84 and BCAX at $21.75 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

BBOT vs BCAX Valuation Comparison 2026 — Intrinsic Value Analysis

BBOT

Biotechnology

BridgeBio Oncology Therapeutics

Quality

6.2

out of 10

Value Trap

—

Price

$8.84

Last close

Models

9/13

Active

BCAX

Biotechnology

Bicara Therapeutics Inc.

Quality

4.3

out of 10

Value Trap

SAFE

Price

$21.75

Last close

Models

7/13

Active

Model-by-Model Comparison

Model	Type	BBOT Fair Value	BBOT Upside	BCAX Fair Value	BCAX Upside
Bayesian DCF	Intrinsic	$2.70	-69.5%	$8.47	-61.1%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$0.10	-98.9%	$3.40	-84.4%
Dynamic NAV	Asset-Based	$3.92	-55.6%	$6.66	-69.4%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for BBOT vs BCAX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

BBOT vs BCAX — Which Stock Is More Undervalued?

BBOT scores higher with a 6.2/10 quality rating vs BCAX's 4.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing BridgeBio Oncology Therapeutics (BBOT) and Bicara Therapeutics Inc. (BCAX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

BBOT currently trades at $8.84 with a QOC of 6.2/10, while BCAX trades at $21.75 with a QOC of 4.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).